RT Generic
T1 Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal
A1 Espejo-Cruz, Maria Lola
A1 Gonzalez-Rubio, Sandra
A1 Zamora-Olaya, Javier
A1 Amado-Torres, Victor
A1 Alejandre, Rafael
A1 Sanchez-Frias, Marina
A1 Ciria, Ruben
A1 De la Mata, Manuel
A1 Rodriguez-Peralvarez, Manuel
A1 Ferrin, Gustavo
K1 hepatocellular carcinoma
K1 liquid biopsy
K1 circulating tumor cells
K1 dynamic changes
K1 therapeutic target
K1 Cancer stem-cells
K1 Mesenchymal transition
K1 Liver-transplantation
K1 Microvascular invasion
K1 Clinical-significance
K1 Peripheral-blood
K1 Early recurrence
K1 Liquid biopsy
K1 Metastasis
K1 Epcam
AB Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and a major cause of cancer-related death worldwide. There is no ideal biomarker allowing early diagnosis of HCC and tumor surveillance in patients receiving therapy. Liquid biopsy, and particularly circulating tumor cells (CTCs), have emerged as a useful tool for diagnosis and monitoring therapeutic responses in different tumors. In the present manuscript, we evaluate the current evidence supporting the quantitative and qualitative assessment of CTCs as potential biomarkers of HCC, as well as technical aspects related to isolation, identification, and classification of CTCs. Although the dynamic assessment of CTCs in patients with HCC may aid the decision-making process, there are still many uncertainties and technical caveats to be solved before this methodology has a true impact on clinical practice guidelines. More studies are needed to identify the optimal combination of surface markers, to increase the efficiency of ex-vivo expansion of CTCs, or even to target CTCs as a potential therapeutic strategy to prevent HCC recurrence after surgery or to hamper tumor progression and extrahepatic spreading.
PB Mdpi
YR 2021
FD 2021-12-01
LK https://hdl.handle.net/10668/25892
UL https://hdl.handle.net/10668/25892
LA en
DS RISalud
RD Apr 12, 2025